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Opioid Prescription Patterns Among Patients With Head and Neck Cancer
Head and neck cancer (HNCA) pain represents a significant physical, psychological, and financial burden for patients.
1 Opioids remain a mainstay of treatment for these patients, and head and neck oncologists must balance the goal of optimal pain control with the risks of abuse. (CCS 014) . The proportion of prescriptions that were opioids, mean payment per opioid prescription, duration of supply, and quantity of opioid prescribed were quantified and compared between HNCA and LCCA cohorts.
Effect sizes were calculated using standardized difference for means (Cohen d) and odds ratio for proportions.
Results | A total of 739 prescriptions associated with HNCA (n = 168) and LCCA (n = 571) diagnoses during the study period were identified and included in the analysis. Patients with HNCA were at significantly greater odds of being prescribed an opioid than patients with LCCA (odds ratio [OR] (Table) .
Discussion | Head and neck cancer diagnoses were associated with significantly greater odds of opioid prescription. Data suggest that patients with HNCA have a higher prevalence of pain than patients with other cancer types, which may explain a necessity for more intensive pain management regimens.
2 In a study of patients undergoing surgery for oral cancer, longterm use of opioids was associated with significantly decreased disease-free survival. 3 Furthermore, there is a significant correlation between physician prescribing patterns and risk of overdose among patients with cancer receiving opioid therapy. 4 Indeed, opiate use is not without risk, and achieving adequate pain management while minimizing the risk of substance overuse and misuse is critical. It is imperative that head and neck cancer physicians are mindful of opioid prescription trends for patients with HNCA, especially in the context of the current opioid epidemic. This study provides preliminary insight into opioid prescription behaviors; however, it is limited by the absence of prior oncologic treatment, tumor stage, and location, as well as comorbid chronic pain conditions. There is an urgent need for further quantification and understanding of postprocedural and chronic opioid use in this patient population. 
